A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

Completed · Phase 1

Conditions studied: Healthy Adult Subjects

In brief

To evaluate the pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy adult participants.

Key facts

Study ID

NCT03381547

Run by

Eli Lilly and Company

People needed

12

Starts

2017-12-18

Expected to finish

2018-02-13

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female between 18 and 55 years of age, inclusive
• Must have a body mass index (BMI) between 19 and 32 (kg/m2) at study Screening
• Must be HIV negative by HIV 1/0/2 testing
• Must be Hepatitis B (HBV) surface antigen negative
• Must be Hepatitis C (HCV) antibody negative
• Females must have a negative serum pregnancy test
• Females of childbearing potential must agree to utilize protocol recommended highly effective contraception methods from Screening throughout the duration of study dosing and for 30 days following the last dose of study drug.
• Must refrain from blood donation from 30 days prior to Day 0 through completion of the study and continuing for at least 30 days from date of last dose of study drug

You may not qualify if…

• Pregnant or lactating subjects
• Have previously participated in an investigational trial involving administration of any investigational compound within 30 days prior to the study dosing
• Have poor venous access and are unable to donate blood
• Have been vaccinated within 90 days of study dosing
• Current alcohol or substance abuse judged by the Investigator to interfere with subject compliance
• Have history of significant drug sensitivity or drug allergy.

Where it is running

• PPD Development — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.